2025

Estcourt, L. J. et al. (2025) Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial. Lancet Haematology, 12(1), e14-e22. (doi: 10.1016/S2352-3026(24)00317-X) (PMID:39642900)

2024

Innes, A. I. et al. (2024) Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy. Leukemia, 38(11), pp. 2443-2455. (doi: 10.1038/s41375-024-02411-7) (PMID:39300220) (PMCID:PMC11518997)

2023

Leak, S., Horne, G. and Copland, M. (2023) Targeting BCR-ABL1-positive leukaemias, a review article. Cambridge Prisms: Precision Medicine, 1, e21. (doi: 10.1017/pcm.2023.9)

2022

Copland, M. et al. (2022) Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. Lancet Haematology, 9(2), e121-e132. (doi: 10.1016/S2352-3026(21)00370-7) (PMID:34906334)

2021

Darici, S. et al. (2021) Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells. Advances in Biological Regulation, 82, 100830. (doi: 10.1016/j.jbior.2021.100830) (PMID:34555701)

Pujol-Navarro, N., Al Qaraghuli, M. M., Kubiak-Ossowska, K., Alsaadi, M. M., Horne, G. A. , Soutar, R. L., Paspali, E., Ferro, V. A., Williams, M. T.S. and Mulheran, P. A. (2021) Multiple myeloma: therapeutic delivery of antibodies and aptamers. Therapeutic Delivery, 12(10), pp. 705-722. (doi: 10.4155/tde-2021-0041) (PMID:34569269)

Horne, G. A. , Laird, J., Latif, A.-L., Irvine, D., Wilson, M. and Douglas, K. (2021) The implications of CAR-T cell therapy on apheresis services: a Scottish perspective. Journal of Clinical Apheresis, 36(3), pp. 513-515. (doi: 10.1002/jca.21871) (PMID:33378123)

2020

Kemp, O., Horne, G. A. and Soutar, R. (2020) The psychological impact of COVID19 on a shielding high-risk cohort. Scottish Medical Journal, 65(4), pp. 120-122. (doi: 10.1177/0036933020951900) (PMID:32838668)

Darici, S., Alkhaldi, H., Horne, G. , Jørgensen, H. G. , Marmiroli, S. and Huang, X. (2020) Targeting PI3K/Akt/mTOR in AML: rationale and clinical evidence. Journal of Clinical Medicine, 9(9), 2934. (doi: 10.3390/jcm9092934) (PMID:32932888) (PMCID:PMC7563273)

Horne, G. et al. (2020) A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia, 34(7), pp. 1775-1786. (doi: 10.1038/s41375-019-0700-9) (PMID:31925317) (PMCID:PMC7224085)

Kinstrie, R. et al. (2020) CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia, 34(6), pp. 1613-1625. (doi: 10.1038/s41375-019-0684-5) (PMID:31896780) (PMCID:PMC7272220)

2019

Fox, T. A., Horne, G. A. , Craddock, C., Cook, G., O'Brien, S., Fox, S., Hockaday, A., Silk, G. and Hillmen, P. (2019) Trial re-investment to build better research for better impact. Lancet, 394(10199), pp. 635-636. (doi: 10.1016/S0140-6736(19)31363-7) (PMID:31448733)

2017

Horne, G. , Jackson, L. , Helgason, V. and Holyoake, T. L. (2017) Stem cell guardians – old and new perspectives in LSC biology. Current Drug Targets, 18(4), pp. 405-413. (doi: 10.2174/1389450117666160712092944) (PMID:27411711)

Horne, G. A. and Copland, M. (2017) Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments. Expert Opinion on Drug Discovery, 12(5), pp. 465-474. (doi: 10.1080/17460441.2017.1303477) (PMID:28277836)

2016

Horne, G. A. , Morrison, H., Campbell, V., Kinstrie, R., Cassels, J., Hair, A., Vetrie, D. , Wheadon, H. , Holyoake, T. L. and Copland, M. (2016) Notch Pathway Activation Targets Leukemic Stem Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML). American Society of Hematology 58th Annual Meeting, San Diego, CA, USA, 3-6 Dec 2016.

2015

Horne, G. A. , Chevassut, T. J.T., Fidler, K. and Wynne, C. (2015) Haemolytic anaemia: don't leave it out in the cold. Archives of Disease in Childhood: Education and Practice, 100(6), pp. 323-330. (doi: 10.1136/archdischild-2014-308132) (PMID:26239653)

Horne, G. A. , Kinstrie, R. and Copland, M. (2015) Novel drug therapies in myelois leukemia: a patent review. Pharmaceutical Patent Analyst, 4(3), pp. 187-205. (doi: 10.4155/ppa.15.3) (PMID:26030080)

Igbineweka, N. E., Horne, G. A. , Jackson, M. B. and Chevassut, T. J. (2015) Low oxygen affinity variant haemoglobin in an elderly woman presenting with low oxygen saturation. Acute Medicine, 14(2), pp. 72-6. (PMID:26305085)

2014

Horne, G. A. , Stewart, H. J.S., Dickson, J., Knapp, S., Ramsahoye, B. and Chevassut, T. (2014) Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1. Stem Cells and Development, 24(7), pp. 879-891. (doi: 10.1089/scd.2014.0302) (PMID:25393219) (PMCID:PMC4367495)

Bisling, K. E., Brewin, J. N., McGovern, A. P., Horne, G. A. , Rider, T., Stewart, H. J., Ramsahoye, B. H. and Chevassut, T. J. (2014) DNMT3A mutations at R882 hotspot are only found in major clones of acute myeloid leukemia. Leukemia and Lymphoma, 55(3), pp. 711-714. (doi: 10.3109/10428194.2013.811580) (PMID:23741974)

2013

Stewart, H. J. S., Horne, G. A. , Bastow, S. and Chevassut, T. J. T. (2013) BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1. Cancer Medicine, 2(6), pp. 826-835. (doi: 10.1002/cam4.146) (PMID:24403256) (PMCID:PMC3892387)

Brewin, J., Horne, G. and Chevassut, T. (2013) Genomic landscapes and clonality of de novo AML. New England Journal of Medicine, 369(15), pp. 1472-1473. (doi: 10.1056/NEJMc1308782) (PMID:24106950) (PMCID:PMC4374653)

Brewin, J. N., Horne, G. A. , Bisling, K. E., Stewart, H. J. and Chevassut, T. J. (2013) Rapid detection of DNMT3A R882 codon mutations allows early identification of poor risk patients with acute myeloid leukemia. Leukemia and Lymphoma, 54(6), pp. 1336-1339. (doi: 10.3109/10428194.2012.736986) (PMID:23035745)

Glew, S., Horne, G. and Ryan, P. (2013) Tips for GP trainees working in haematology. British Journal of General Practice, 63(611), pp. 333-334. (doi: 10.3399/bjgp13X668429) (PMID:23735406) (PMCID:PMC3662452)

2012

Horne, G.A. and Chevassut, T. (2012) Pregnancy in Shwachman-Diamond syndrome: a novel genetic mutation with minimal consequence. BMJ Case Reports, 2012(oct31), bcr2012007. (doi: 10.1136/bcr-2012-007305) (PMID:23125299) (PMCID:PMC4543924)

Horne, G. , Brewin, J. and Chevassut, T. (2012) Genetic profiling in acute myeloid leukemia. New England Journal of Medicine, 366(24), pp. 2321-2322. (doi: 10.1056/NEJMc1204662) (PMID:22694006)

Jones, C.I., Zabolotskaya, M.V., King, A.J., Stewart, H.J.S., Horne, G.A. , Chevassut, T.J. and Newbury, S.F. (2012) Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. British Journal of Cancer, 107(12), pp. 1987-1996. (doi: 10.1038/bjc.2012.525) (PMID:23169280) (PMCID:PMC3516695)

Articles

Estcourt, L. J. et al. (2025) Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial. Lancet Haematology, 12(1), e14-e22. (doi: 10.1016/S2352-3026(24)00317-X) (PMID:39642900)

Innes, A. I. et al. (2024) Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy. Leukemia, 38(11), pp. 2443-2455. (doi: 10.1038/s41375-024-02411-7) (PMID:39300220) (PMCID:PMC11518997)

Leak, S., Horne, G. and Copland, M. (2023) Targeting BCR-ABL1-positive leukaemias, a review article. Cambridge Prisms: Precision Medicine, 1, e21. (doi: 10.1017/pcm.2023.9)

Copland, M. et al. (2022) Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. Lancet Haematology, 9(2), e121-e132. (doi: 10.1016/S2352-3026(21)00370-7) (PMID:34906334)

Darici, S. et al. (2021) Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells. Advances in Biological Regulation, 82, 100830. (doi: 10.1016/j.jbior.2021.100830) (PMID:34555701)

Pujol-Navarro, N., Al Qaraghuli, M. M., Kubiak-Ossowska, K., Alsaadi, M. M., Horne, G. A. , Soutar, R. L., Paspali, E., Ferro, V. A., Williams, M. T.S. and Mulheran, P. A. (2021) Multiple myeloma: therapeutic delivery of antibodies and aptamers. Therapeutic Delivery, 12(10), pp. 705-722. (doi: 10.4155/tde-2021-0041) (PMID:34569269)

Horne, G. A. , Laird, J., Latif, A.-L., Irvine, D., Wilson, M. and Douglas, K. (2021) The implications of CAR-T cell therapy on apheresis services: a Scottish perspective. Journal of Clinical Apheresis, 36(3), pp. 513-515. (doi: 10.1002/jca.21871) (PMID:33378123)

Kemp, O., Horne, G. A. and Soutar, R. (2020) The psychological impact of COVID19 on a shielding high-risk cohort. Scottish Medical Journal, 65(4), pp. 120-122. (doi: 10.1177/0036933020951900) (PMID:32838668)

Darici, S., Alkhaldi, H., Horne, G. , Jørgensen, H. G. , Marmiroli, S. and Huang, X. (2020) Targeting PI3K/Akt/mTOR in AML: rationale and clinical evidence. Journal of Clinical Medicine, 9(9), 2934. (doi: 10.3390/jcm9092934) (PMID:32932888) (PMCID:PMC7563273)

Horne, G. et al. (2020) A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia, 34(7), pp. 1775-1786. (doi: 10.1038/s41375-019-0700-9) (PMID:31925317) (PMCID:PMC7224085)

Kinstrie, R. et al. (2020) CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia, 34(6), pp. 1613-1625. (doi: 10.1038/s41375-019-0684-5) (PMID:31896780) (PMCID:PMC7272220)

Fox, T. A., Horne, G. A. , Craddock, C., Cook, G., O'Brien, S., Fox, S., Hockaday, A., Silk, G. and Hillmen, P. (2019) Trial re-investment to build better research for better impact. Lancet, 394(10199), pp. 635-636. (doi: 10.1016/S0140-6736(19)31363-7) (PMID:31448733)

Horne, G. , Jackson, L. , Helgason, V. and Holyoake, T. L. (2017) Stem cell guardians – old and new perspectives in LSC biology. Current Drug Targets, 18(4), pp. 405-413. (doi: 10.2174/1389450117666160712092944) (PMID:27411711)

Horne, G. A. and Copland, M. (2017) Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments. Expert Opinion on Drug Discovery, 12(5), pp. 465-474. (doi: 10.1080/17460441.2017.1303477) (PMID:28277836)

Horne, G. A. , Chevassut, T. J.T., Fidler, K. and Wynne, C. (2015) Haemolytic anaemia: don't leave it out in the cold. Archives of Disease in Childhood: Education and Practice, 100(6), pp. 323-330. (doi: 10.1136/archdischild-2014-308132) (PMID:26239653)

Horne, G. A. , Kinstrie, R. and Copland, M. (2015) Novel drug therapies in myelois leukemia: a patent review. Pharmaceutical Patent Analyst, 4(3), pp. 187-205. (doi: 10.4155/ppa.15.3) (PMID:26030080)

Igbineweka, N. E., Horne, G. A. , Jackson, M. B. and Chevassut, T. J. (2015) Low oxygen affinity variant haemoglobin in an elderly woman presenting with low oxygen saturation. Acute Medicine, 14(2), pp. 72-6. (PMID:26305085)

Horne, G. A. , Stewart, H. J.S., Dickson, J., Knapp, S., Ramsahoye, B. and Chevassut, T. (2014) Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1. Stem Cells and Development, 24(7), pp. 879-891. (doi: 10.1089/scd.2014.0302) (PMID:25393219) (PMCID:PMC4367495)

Bisling, K. E., Brewin, J. N., McGovern, A. P., Horne, G. A. , Rider, T., Stewart, H. J., Ramsahoye, B. H. and Chevassut, T. J. (2014) DNMT3A mutations at R882 hotspot are only found in major clones of acute myeloid leukemia. Leukemia and Lymphoma, 55(3), pp. 711-714. (doi: 10.3109/10428194.2013.811580) (PMID:23741974)

Stewart, H. J. S., Horne, G. A. , Bastow, S. and Chevassut, T. J. T. (2013) BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1. Cancer Medicine, 2(6), pp. 826-835. (doi: 10.1002/cam4.146) (PMID:24403256) (PMCID:PMC3892387)

Brewin, J., Horne, G. and Chevassut, T. (2013) Genomic landscapes and clonality of de novo AML. New England Journal of Medicine, 369(15), pp. 1472-1473. (doi: 10.1056/NEJMc1308782) (PMID:24106950) (PMCID:PMC4374653)

Brewin, J. N., Horne, G. A. , Bisling, K. E., Stewart, H. J. and Chevassut, T. J. (2013) Rapid detection of DNMT3A R882 codon mutations allows early identification of poor risk patients with acute myeloid leukemia. Leukemia and Lymphoma, 54(6), pp. 1336-1339. (doi: 10.3109/10428194.2012.736986) (PMID:23035745)

Glew, S., Horne, G. and Ryan, P. (2013) Tips for GP trainees working in haematology. British Journal of General Practice, 63(611), pp. 333-334. (doi: 10.3399/bjgp13X668429) (PMID:23735406) (PMCID:PMC3662452)

Horne, G.A. and Chevassut, T. (2012) Pregnancy in Shwachman-Diamond syndrome: a novel genetic mutation with minimal consequence. BMJ Case Reports, 2012(oct31), bcr2012007. (doi: 10.1136/bcr-2012-007305) (PMID:23125299) (PMCID:PMC4543924)

Horne, G. , Brewin, J. and Chevassut, T. (2012) Genetic profiling in acute myeloid leukemia. New England Journal of Medicine, 366(24), pp. 2321-2322. (doi: 10.1056/NEJMc1204662) (PMID:22694006)

Jones, C.I., Zabolotskaya, M.V., King, A.J., Stewart, H.J.S., Horne, G.A. , Chevassut, T.J. and Newbury, S.F. (2012) Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. British Journal of Cancer, 107(12), pp. 1987-1996. (doi: 10.1038/bjc.2012.525) (PMID:23169280) (PMCID:PMC3516695)

Conference or Workshop Item

Horne, G. A. , Morrison, H., Campbell, V., Kinstrie, R., Cassels, J., Hair, A., Vetrie, D. , Wheadon, H. , Holyoake, T. L. and Copland, M. (2016) Notch Pathway Activation Targets Leukemic Stem Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML). American Society of Hematology 58th Annual Meeting, San Diego, CA, USA, 3-6 Dec 2016.